title: Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults.
abstract: The survival of Bifidobacterium animalis strain DN-173 010 was assessed after its ingestion in a fermented product or in a lyophilised form. Twelve healthy subjects were included in a randomised, open study with 2 parallel groups. The composition and activities of the faecal microbiota were monitored before (10-day baseline step), during (1-week product administration step) and after (10-day follow-up step) the ingestion of 1 of the 2 products. A colony immunoblotting method, fluorescent in situ hybridisation with group-specific DNA probes, and temporal temperature gradient gel electrophoresis using group-specific primers were carried out to compare survival of B. animalis strain DN-173 010 after ingestion of the 2 products, together with analyses of enzyme activities and faecal metabolites. At the end of the supplementation step, the mean number of B. animalis DN-173 010 quantified by immunodetection in the faeces of 5 of 6 subjects in each treatment group was >/=10(8) colony-forming units/g faeces. These numbers corresponded to an average survival of 22% for the lyophilised form and 20% for the fermented product. At the same step, the PCR temporal temperature gradient gel electrophoresis profiles showed a double band corresponding to the B. animalis DN-173 010 pattern for 11 subjects. No major modification was observed during the trial in either the dominant members of the faecal microbiota assessed by fluorescent in situ hybridisation or their activities. In conclusion, we show that the lyophilised form of B. animalis DN-173 010 survives transit and could represent a more convenient form to administer for long-term clinical trials.
authors.affiliation: Unité d'Ecologie et Physiologie du Système Digestif, Institut National de la Recherche Agronomique, Jouy-en-Josas, France. rochet@jouy.inra.fr
authors.forename: Violaine
authors.initials: V
authors.lastname: Rochet
authors.forename: Lionel
authors.initials: L
authors.lastname: Rigottier-Gois
authors.forename: Audrey
authors.initials: A
authors.lastname: Ledaire
authors.forename: Claude
authors.initials: C
authors.lastname: Andrieux
authors.forename: Malène
authors.initials: M
authors.lastname: Sutren
authors.forename: Sylvie
authors.initials: S
authors.lastname: Rabot
authors.forename: Agnès
authors.initials: A
authors.lastname: Mogenet
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Bresson
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Cools
authors.forename: Céline
authors.initials: C
authors.lastname: Picard
authors.forename: Nathalie
authors.initials: N
authors.lastname: Goupil-Feuillerat
authors.forename: Joël
authors.initials: J
authors.lastname: Doré
mesh_terms: D000328:Adult; D001644:Bifidobacterium / Q000254:growth & development* / Q000302:isolation & purification; D015169:Colony Count, Microbial; D043302:Cultured Milk Products / Q000382:microbiology*; D005243:Feces / Q000382:microbiology*; D005260:Female; D005434:Flow Cytometry; D005612:Freeze Drying / Q000379:methods*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage*; D016896:Treatment Outcome